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SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain 
scaffolding protein involved in various key cellular processes, including the 
removal of damaged mitochondria by its function as a selective autophagy 
receptor. Heterozygous variants in SQSTM1 have been associated with Paget 
disease of the bone and might contribute to neurodegeneration in amyotrophic 
lateral sclerosis (ALS) and frontotemporal dementia (FTD). Using exome 
sequencing, we identified three different biallelic loss-of-function variants in 
SQSTM1 in nine affected individuals from four families with a childhood- or 
adolescence-onset neurodegenerative disorder characterized by gait 
abnormalities, ataxia, dysarthria, dystonia, vertical gaze palsy, and cognitive 
decline. We confirmed absence of the SQSTM1/p62 protein in affected 
individuals` fibroblasts and found evidence of a defect in the early response to 
mitochondrial depolarization and autophagosome formation. Our findings 
expand the SQSTM1-associated phenotypic spectrum, and lend further support 
to the concept of disturbed selective autophagy pathways in 
neurodegenerative diseases.  
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Neurodegenerative disease causes severe disability or even early death and many 
families and affected individuals remain without a specific molecular diagnosis. The 
identification of underlying gene defects in both common and rare conditions 
provided fundamental new insights into pathophysiology and basic cellular 
processes. Examples are the discovery of gene defects underlying Parkinson 
disease (PD) and amyotrophic lateral sclerosis (ALS). Proteins encoded by affected 
genes such as PARKIN (PARK2), PINK1, OPTN, SQSTM1/p62, and TBK1 offer a 
new perspective on the involvement of mitochondria. Specifically, these proteins are 
thought to be involved in the maintenance of a functioning pool of mitochondria by 
regulating their turnover by selective autophagocytic processes.1; 2 One recent model 
suggests that after loss of mitochondrial membrane potential or accumulation of 
misfolded proteins, PINK1 generates a phospho-ubiquitin signature on mitochondria 
to induce recruitment of the primary autophagy adaptors OPTN and NDP52 which 
than engage with the autophagy machinery (ULK1, DFCP1, WIPI1, and LC3.3 While 
TBK1-dependent phosphorylation of OPTN and NDP52 is thought to be crucial for 
robust mitophagy, the presence of additional/alternative autophagy adaptors such as 
TAX1BP1, NRB1, and SQSTM1/p62 is dispensable for mitophagy itself.3 
In addition to its function in autophagy, the multidomain scaffold protein 
SQSTM1/p62 plays a role in diverse other key cellular pathways; heterozygous 
SQSTM1 (MIM: *601530) variants have been suggested to contribute to the 
pathogenesis of such diverse presentations as Paget disease of the bone (PDB, 
MIM: #167250), ALS and FTD (MIM: #616437),4 and recently distal myopathy with 
rimmed vacuoles.5 Here, we report on the phenotypic spectrum associated with 
absence of SQSTM1/p62 as well as the results of our studies of mitophagy-related 
phenotypes in mutant fibroblast cell lines. 
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We performed exome sequencing on genomic DNA from affected individuals from 
four families with a so far etiologically unresolved childhood- or adolescence-onset 
neurodegenerative syndrome manifesting with gait abnormalities and ataxia. Clinical 
and genetic findings are summarized in Table 1, pedigrees are shown in Figure 1, 
and neuroimaging findings in Figure 2. A summary of the phenotypes is provided 
below, while the detailed individual case reports are provided in the supplemental 
data. Informed consent was obtained from all affected individuals or their guardians. 
The study was approved by the local ethics committees. 
Family 1 consists of three affected siblings, one male (F1:II.1) and two females 
(F1:II.3, F1:II.6), and three healthy siblings, born to healthy unrelated parents of 
German origin. All affected individuals presented with gait problems in their early 
teen years, progressing to wheelchair-dependence at ages 16-32 years. Other 
presenting symptoms included urinary incontinence, upper limb ataxia, and cognitive 
decline. Last clinical examination at ages 45, 42, and 33 years, respectively, revealed 
generalized dystonia, dysarthria, and a cerebellar syndrome in all three affected 
siblings, as well as vertical gaze palsy and a pyramidal syndrome in two. None had a 
history of psychiatric symptoms, seizures, tremor or visual impairment. Brain MRI 
showed accumulation of iron in basal ganglia in individuals F1:II.3 and F1:II.6 (Figure 
2). A muscle biopsy in F1:II.6 was unremarkable regarding morphology, 
histochemistry, ultrastructure, and mitochondrial enzyme analysis. 
Family 2 consists of three affected sisters (F2:II.2, F2:II.3, F2:II.4) and nine reportedly 
healthy siblings, born to healthy parents from the United Arab Emirates who were 
unaware of consanguinity. All affected siblings had a remarkably similar course with 
unsteadiness of gait, coordination problems and cognitive decline from the age of 10 
years. At last clinical examination at ages 31, 18, and 12 years, respectively, all were 
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still able to walk independently but showed short and thin stature, a cerebellar 
syndrome, marked vertical gaze palsy, hearing loss, and a dystonic or athetotic 
movement disorder. Brain MRI showed mild cerebellar atrophy in all affected siblings 
(Figure 2).  
Family 3 consists of one affected sister (F3:II.1) and one healthy brother, born to 
healthy unrelated parents from Finland. The affected sister presented at the age of 7 
years with tremor, oculomotor apraxia and dysarthria. Last clinical examination at 
age 18 years showed a cerebellar syndrome and cognitive impairment. Brain MRI 
revealed mild to moderate cerebellar atrophy (Figure 2). Muscle biopsy was 
unremarkable regarding morphology, histochemistry, and ultrastructure but 
respiratory chain enzyme analysis showed a slight decrease in complex IV activity. 
Family 4 consists of two affected individuals, one female (F4:II.1) and one male 
(F4:II.4), and two healthy siblings, born to healthy consanguineous parents of 
Kurdish descent. Both affected siblings presented at the age of 8 years with a 
syndrome of ataxia, dysarthria, and vertical gaze palsy. Last clinical examination at 
ages 33 and 17 years, respectively, revealed a cerebellar syndrome and cognitive 
impairment. While F4:II.1 is still walking with a broad-based gait at age 33 years, her 
brother F4:II.4 is wheelchair-bound at age 17 years. Brain MRI and EEG showed 
normal findings in both. In F4:II:4, mitochondrial ATP production rate and respiratory 
chain enzyme activities were towards the lower end of normal, with complex IV 
activity being mostly affected. In agreement with this, fibroblasts grown on galactose 
as carbon source showed a mild complex IV defect (Figure S1). 
We performed exome sequencing at three centers [Munich (families 1 and 2), 
Helsinki (family 3), and Stockholm (family 4)] on genomic DNA from three affected 
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individuals of family 1, individuals F2:II.2, F3:II.1 as well as on both affected 
individuals and their parents of family 4, essentially as described previously.6 
In family 1, individuals F1:II.1 and F1:II.3 have been investigated in a first experiment 
with a SureSelect Human All Exon 38 Mb enrichment kit (Illumina). A search for 
recessive-type non-synonymous variants with a minor allele frequency (MAF) < 
0.1 % in an in-house database containing 7,000 control exomes and the Exome 
Aggregation Consortium (ExAC) Server (Cambridge, MA [09/2015]) failed to prioritize 
likely pathogenic variants common to both individuals. We speculated that we had 
missed the responsible variant due to insufficient coverage of target sequences and 
processed DNA of the third affected individual F1:II.6 with an updated version of the 
enrichment kit, SureSelect Human All Exon 50 Mb V3, potentially providing an 
improved coverage of the coding regions. This analysis identified 7 genes carrying 
potential compound heterozygous or homozygous variants with SQSTM1 being the 
only gene carrying two predicted loss-of-function alleles (Table S1). Manual 
inspection of the sequencing data confirmed that the SQSTM1 (GenBank: 
NM_003900.4) variant c.2T>A, p.(?) in exon 1 was missed as an alternative call in 
the exome datasets of the two other siblings due to insufficient coverage of this 
genomic position, which reflects a general problem of GC-rich first exons. 
Subsequent Sanger sequencing confirmed the c.2T>A variant in a homozygous state 
in all affected individuals with the mother and healthy siblings being heterozygotes or 
wild-types. These results were in line with the observation that the SQSTM1 locus is 
located within one of six regions of interest of a previously performed SNP-array 
linkage study performed on this family. As no paternal samples were available for 
carrier testing, we cannot exclude a large deletion on the paternal chromosome. 
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However, analysis of the gene dosage in individuals’ F1:II.6 exome dataset using 
exome depth as described previously did not indicate any copy number variation.7; 8 
In individual F2:II.2, sequencing was performed using a SureSelect Human All Exon 
38 Mb enrichment kit. A search for genes carrying putative compound heterozygous 
or homozygous rare variants identified 30 candidate genes, 7 of which affected by 
variants rated a likely detrimental in silico (see Table S1). Segregation analysis by 
Sanger sequencing on DNAs of further family members excluded a likely clinical 
relevance of variants in five putative candidate genes leaving a homozygous 
frameshift variant c.311_312del, p.(Glu104Valfs*48) in SQSTM1 as the likely 
candidate. No material was available to confirm a heterozygous carrier status of the 
father. However, we did not detect any evidence of a large heterozygous deletion in 
the exome data of individual F2:II.2.8 
In individual F3:II.1, the exome targets of the affected individual’s DNA were captured 
with the Agilent SureSelect Human All Exon V5 whole exome kit followed by 
sequencing with the Illumina HiSeq 2000 platform. The variant calling pipeline of the 
Finnish Institute of Molecular Medicine (FIMM) was used for the reference genome 
alignment and variant calling.9 Variants with a Combined Annotation Dependent 
Depletion (CADD) C-score under 10 were excluded.10 A search for recessive-type 
non-synonymous variants with a MAF < 0.1 % on the ExAC Server (Cambridge, MA 
[09/2015]) prioritized three candidate genes, LLGL1 (MIM: *600966), RYR1 (MIM: 
*180901), and SQSTM1. Variants in RYR1 have been associated with unrelated 
autosomal recessive inherited phenotypes (MIM: #255320 and #117000). Variants in 
LLGL1 have so far not been associated with human disease and although an effect 
of the predictively synonymous variant on splicing cannot be excluded we considered 
it unlikely to be associated with the disease of individual F3:II.1. A homozygous 
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SQSTM1 loss-of-function variant with a CADD score of 45, c.286C>T, p.(Arg96*), 
remained as the top scoring candidate. 
Family 4 was sequenced on the Hiseq 2500 platform (Illumina) using the Agilent 
SureSelect Human All Exon V4 whole exome kit. The resulting sequences were 
analyzed using an in-house Mutation Identification Pipeline (MIP) as previously 
described.11 All called variants are scored and ranked using the Mutation 
Identification Pipeline weighted sum model, which uses multiple parameters, but 
emphasizes Mendelian inheritance patterns, conserved, rare, and protein-damaging 
variants. This left a homozygous c.286C>T, p.(Arg96*) SQSTM1 loss-of-function 
variant as the top scoring variant. Sanger sequencing of parents and affected siblings 
confirmed that the SQSTM1 variant co-segregated with the phenotype in line with 
autosomal recessive inheritance. 
Biallelic loss-of-function SQSTM1 variants were absent from 7,000 in-house exomes 
(Munich) of individuals with unrelated phenotypes and no such homozygous variants 
were observed in ~ 120,000 alleles of the ExAC Server (Cambridge, MA [09/2015]). 
Western blot studies in primary fibroblasts available from individuals F1:II.6, F3.II.1, 
F4:II.1, and F4:II.4 showed absence of the SQSTM1/p62 protein accompanied by a 
severe reduction in SQSTM1 mRNA steady-state levels in fibroblasts from individuals 
F4:II.1,4 (Figure 3). In summary, the identification of three different biallelic SQSTM1 
loss-of-function variants in four unrelated families with a similar clinical phenotype 
establishes SQSTM1 as a gene confidently implicated in this neurodegenerative 
disease. The identified variants c.286C>T, p.(Arg96*) and c.311_312del, 
p.(Glu104Valfs*48) affect all three predicted SQSTM1 isoforms. In contrast, the 
variant c.2T>A, p.(?) affects only the start codon of one out of three predicted 
isoforms, and while arguing for the importance of this isoform in the pathogenesis of 
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the disease it raises the possibility of residual mRNA/protein amount. RNA 
sequencing in fibroblasts and whole blood suggested partial expression of the two 
other isoforms (Figure S2). However, the antibody directed against the C-terminus of 
the SQSTM1/p62 protein common to all three isoforms failed to provide evidence of 
any translated SQSTM1 gene products, at least in fibroblasts.  
The mutation c.286C>T has been detected in families F3 and F4. In order to test for 
the possibility of a shared ancestral change, we compared the variation observed in 
the ~2 Mb region surrounding the variant. Identified rare (MAF < 1 % in public 
databases) variants were not shared between subjects of families 3 and 4 carrying 
the c.286C>T variant, implicating that this is unlikely a single ancestral variant but 
arose independently in the two families, in line with the reportedly Finnish and 
Kurdish descent of families 3 and 4, respectively. 
The scaffold protein SQSTM1/p62 is highly conserved among metazoans and was 
originally identified as a signal adaptor for the atypical protein kinases C sub-family 
(aPKCs).12; 13 SQSTM1/p62 serves as a signaling hub in a variety of key cellular 
processes such as cell differentiation, cell growth, osteoclastogenesis, 
tumorigenesis, amino acid sensing, and oxidative stress response.14; 15 Its 
interactions with binding partners are mediated by multiple domains (Figure 1). 
SQSTM1/p62 is found in different compartments of the cell including the cytoplasm, 
nucleus, autophagosomes, and lysosomes. Upon stress-induction, SQSTM1/p62 is 
activated to enable selective autophagy, e.g. ofcells infected by bacteria, protein 
aggregates, and damaged mitochondria.16-20 Earlier studies had suggested that 
SQSTM1/p62 is responsible for the PARKIN-mediated direction of ubiquitinated 
mitochondria to the autophagosome.17 However, growing evidence indicates that 
SQSTM1/p62 is not essential for mitophagy itself3; 18 but seems to be indispensable 
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for perinuclear clustering of depolarized mitochondria in a process of self-
oligomerization.3; 18; 19 Furthermore, TBK1-dependent phosphorylation of 
SQSTM1/p62 at Ser403 has been shown to promote the efficacy of autophagosomal 
engulfment of ubiquitinated mitochondria at an early phase of mitochondrial 
depolarization.21 We therefore studied perinuclear clustering and clearance of 
mitochondria in naïve as well as GFP-PARKIN- and YFP-PARKIN-overexpressing 
control and SQSTM1/p62 variant fibroblasts after depolarization of mitochondria with 
the protonophore carbonyl cyanide m-chlorophenyl hydrazine (CCCP), the 
established tool to study PARKIN-dependent mitophagy in cultured cells. In naïve 
SQSTM1/p62 variant cell lines, reduced perinuclear clustering of mitochondria was 
detected after 3 h CCCP treatment compared to control cells (Figure 4, panel A). In 
PARKIN-overexpressing cells (transduced with GFP-PARKIN or transfected with 
YFP-PARKIN), depolarization of mitochondria and subsequent collapse of the 
mitochondrial network led to a translocation of PARKIN to the mitochondria as 
indicated by co-localization with mtSSBP (Figure S3) and TOM20 (Figure 4, panel B), 
replicating results of a wide literature in the field.3; 18 After 2 h of CCCP treatment, we 
found a clear mitochondrial clustering in control YFP-PARKIN-overexpressing cells 
but not in SQSTM1/p62 variant cells (Figure 4, panel B). No perinuclear clustering of 
mitochondria was observed after 2 h treatment of oligomycin and antimycin (Figure 
S4). Differences in perinuclear clustering were less obvious between stably 
overexpressing GFP-PARKIN control and SQSTM1/p62 variant fibroblasts after 3 h 
of CCCP treatment (Figure S3). We observed no difference in the overall clearance 
of mitochondria after 24 h CCCP treatment in all tested conditions, in line with 
SQSTM1/p62 being dispensable for the PARKIN-dependent disposal of depolarized 
mitochondria in fibroblasts (Figure S3 and Figure S4). In agreement, we observed no 
difference in mitochondrial clearance in PARKIN-overexpressing cells, treated with 
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the respiratory chain inhibitors oligomycin and antimycin after 24 h (Figure S4) in 
these cells. We next investigated the autophagic flux in SQSTM1/p62-deficient and 
control cell lines by monitoring changes in the levels of LC3I/II upon starvation with 
and without addition of the lysosomal inhibitors bafilomycin or NH4Cl. Concordant 
with a functional redundancy of involved autophagy adaptors, we observed no 
obvious differences between control and SQSTM1/p62 variant cell lines in these 
assays (Figures S5 and S6). Colocalization of the autophagosomal marker LC3II and 
YFP-PARKIN was not affected upon CCCP treatment (Figure S7). However, 
depolarisation of mitochondria with CCCP did result in a reduced autophagosome 
formation in naïve SQSTM1/p62-deficient cells (Figure 4, panels C and D) while after 
treatment with oligomycin-antimycin no differences were observed between 
SQSTM1/p62 variant and control cell lines (Figure S8). These observations suggest 
that in dividing cells SQSTM1/p62 contributes to the early regulation of mitophagy 
including perinuclear clustering of mitochondria and autophagosome formation upon 
depolarization, but is redundant for mitochondrial removal and autophagic flux. 
In mice, the knock-out of Sqstm1 leads to mature-onset obesity, leptine resistance, 
as well as impaired glucose tolerance and insulin resistance potentially mediated by 
disturbed regulation of adipocyte differentiation due to enhanced basal ERK 
activity.22 Furthermore, the chronic absence of Sqstm1/p62 promotes mature-onset 
neurodegeneration with accumulation of hyperphosphorylated tau and neurofibrillary 
tangles in hippocampal and cortical neurons manifesting with increased anxiety, 
depression, and loss of short-term memory.23 In agreement, individuals deficient of 
SQSTM1/p62 did present with severely increased tau and phospho-tau levels in CSF 
(see F4:II.1,4 clinical description). 
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To our knowledge, biallelic SQSTM1 loss-of-function mutations have not yet been 
reported in humans. The present study establishes absence of SQSTM1/p62 as a 
molecular defect underlying a childhood- or adolescence-onset neurodegenerative 
disorder. The pivotal features of the affected individuals’ phenotypes were gait 
abnormalities (9/9), ataxia mostly of the upper limbs (9/9), dysarthria (9/9), dystonia 
(7/9), vertical gaze palsy (7/9), and mild cognitive decline (7/9). The course was 
remarkably similar in all 9 affected individuals with onset between age 7 to 15 years 
and relatively slow progression. Brain MRI showed cerebellar atrophy in 4 out of 8 
individuals, and signal abnormalities in basal ganglia with iron accumulation in 2 out 
of 8 individuals. Of note, extensive brain iron deposition in the basal ganglia and 
substantia nigra is a characteristic phenotypic feature of a clinically and genetically 
heterogeneous group of neurodegenerative disorders subsumed under the umbrella 
term NBIA (neurodegeneration with brain iron accumulation).24 While the exact 
pathomechanisms leading to neurodegeneration is unknown in most of the major 
NBIA forms, the identification of X-chromosomal WDR45 (MIM: *300526) mutations 
in individuals with BPAN (NBIA 5, MIM: #300894) suggested defective autophagy as 
a key pathomechanism.25 Screening of a large cohort of 250 idiopathic NBIA 
individuals for SQSTM1 variants failed to detect clinically relevant biallelic variants 
indicating that brain iron accumulation is likely an inconsistent feature in SQSTM1-
associated neurodegeneration. Of note, also in the PLA2G6 (MIM: *603604)-
associated NBIA subtype PLAN (MIM: #610217), brain iron accumulation may be 
absent or subtle early in the disease course.24  
Given the role of SQSTM1/p62 as a key player in a variety of vital cellular processes, 
it was unexpected that its absence is compatible with survival above age 40 years 
and that affected individuals display such a circumscribed neurological phenotype. 
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This observation together with the findings in mice argues for a redundancy of 
involved factors and pathways or effective compensatory mechanisms to maintain 
cellular homeostasis. Our data indicates that SQSTM1/p62 functions are of particular 
importance in the brain, where the postmitotic nature of neurons poses especial 
challenges to the removing of damaged organelles and misfolded proteins. 
In humans, heterozygous missense and truncating SQSTM1 variants have been 
associated with the progressive skeletal disorder Paget disease of the bone (PDB), 
the neurodegenerative disorders ALS and FTD4, and recently distal myopathy with 
rimmed vacuoles.5 Furthermore, 5q copy number gains comprising SQSTM1 have 
been associated with kidney cancer.26 While several disease alleles are common to 
both PDB and ALS/FTD, others have been proposed to be ALS/FTD-specific.4 
Surprisingly, heterozygous carriers of SQSTM1 variants in our families showed no 
skeletal defects or neurological disease. In keeping with this, a recent large exome 
sequencing study of 2,869 ALS cases and 6,405 controls, which confidently 
implicated TBK1 (MIM: *604834) and OPTN (MIM: *602432) in ALS, failed to 
establish a significant enrichment of rare SQSTM1 variants relative to controls.27 
Therefore, despite SQSTM1 being a promising ALS candidate gene from a cell 
biological perspective, additional statistical and mechanistic evidence is needed for 
the implication of hypomorphic alleles, putatively dominant-acting variants or 
SQSTM1 haploinsufficiency in neurodegeneration. The puzzling variety of diseases 
and inheritance patterns associated with SQSTM1 variants suggests complex 
genotype/phenotype relationships and points to the possibility of currently 
unidentified modifying genes and gene-environment interactions.  
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SUPPLEMENTAL DATA 
Supplemental Data include clinical descriptions, seven figures, and one table. 
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FIGURE TITLES AND LEGENDS 
 
Figure 1. Pedigrees of Investigated Families and Structure of SQSTM1 
(A) Pedigrees of four families with mutations in SQSTM1. Mutation status of affected 
(closed symbols) and healthy (open symbols) family members. n.d., not determined. 
(B) Gene structure of SQSTM1 with known protein domains and motifs of the gene 
product and localization of the identified mutations. Intronic regions are not drawn to 
scale. PB1, Phox 1 abd Bem1p; ZZ, zinc finger; TRAF6, tumor necrosis factor 
receptor-associated factor 6; LIR, LC3-interaction region; KIR, Keap1-interacting; 
UBA, ubiquitin-associated. 
 
Figure 2. Neuroimaging Findings in SQSTM1/p62 variant Individuals 
(A) Brain MRI (T2-weigthed image, axial view) of individual F1:II.6 at the age of 33 
years, demonstrating iron accumulation in the globus pallidus internus. 
(B) Brain MRI (T1-weigthed image, sagittal view) of individual F2:II.2 at the age of 31 
years, demonstrating mild cerebellar atrophy. 
(C) Brain MRI (T1-weighted image, sagittal view) of individual F3:II.1 at the age of 18 
years showing mild to moderate upper vermian atrophy. 
 
Figure 3. Investigation of SQSTM1/p62 Protein and RNA Levels 
Western blot studies in SQSTM1/p62 variant fibroblast cell lines indicating that the 
homozygous variants c.2T>A, p.(?) and c.286C>T, p.(Arg96*) result in a loss of 
SQSTM1/p62 protein. Immunoblotting was done with anti-SQSTM1/p62 antibody 
(F1:II.6 with Progen, GP62-C; F3:II.1 and F4:II.1,4 with Cell Signaling, #5114).  
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In SQSTM1/p62 variant fibroblasts cell lines of F4:II.1,4 total RNA was isolated for 
qPCR analysis using Trizol. Reverse transcription for qRT-PCR analysis was 
performed using High Capacity cDNA Reverse Transcription Kit (Life Technologies). 
qRT-PCR was performed on a QuantStudio 6 (Life Technologies) with Platinum 
SYBR Green qPCR supermix-UDG (Life Technologies) and gene-specific primers. 
Error bars indicate ± SEM; ***, p ≤ 0.001; two-tailed unpaired t-test. 
 
Figure 4. Investigation of Aggregation of Depolarized Mitochondria and 
Autophagosomal Formation 
(A) Naïve (no exogenous PARKIN) control and SQSTM1/p62 variant fibroblasts were 
treated with 20 µM CCCP for 3 and 6 h and fixed with 4 % PFA. Mitochondria were 
immunostained with the mitochondrial SSBP, detected with a fluorescent-labelled 
secondary antibody (AF568, red), nuclei stained with DAPI (blue), and images 
acquired by confocal microscopy. Depolarization of mitochondria using the 
protonophore CCCP led to the collapse of the mitochondrial network in control and in 
SQSTM1/p62 variant cells. After 3 h of CCCP treatment, perinuclear clustering of 
mitochondria can be observed in control cells, which is less evident in SQSTM1/p62 
variant fibroblasts (arrows indicate distance from outer cell membrane to clustered 
mitochondria). No obvious differences between cell lines were observed after 6 h of 
treatment. 
(B) Control and SQSTM1/p62 variant fibroblasts were transfected with YFP-Parkin 
(Addgene #23955),28 treated with CCCP (20 µM) for 2 h, followed by 4 % PFA 
fixation. Mitochondria were immunostained using antibodies against the 
mitochondrial protein TOM20 (sc-11414, Santa Cruz) and detected with a 
fluorescent-labelled secondary antibody (AF568, red). Images were acquired by 
confocal microscopy. Depolarization of mitochondria using the protonophore CCCP 
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led to the collapse of the mitochondrial network in control and in SQSTM1/p62 
variant cells. After 2 h mitochondrial clustering can be observed in control cells, with 
reduced clustering in SQSTM1/p62-deficient cells. Right panel: quantification of % of 
cells showing a dispersed or aggregated mitochondrial distribution after 2 h of CCCP 
treatment. n=3, 25 cells per experiment. Morphology classification was done 
following previous reports studying the function of p62/SQSTM1 in mitophagy. 
(C) SQSTM1/p62 variant and control cell lines were treated for 24 h with the 
protonophore CCCP (20 µM) and fixed with 4 % PFA. Autophagosomes were 
immunostained, using antibodies against the autophagosomal protein LC3II (M152-3, 
MBL) and detected with a fluorescent-labelled secondary antibody (AF488, green). 
Images were acquired by fluorescence microscopy and autophagosomes were 
counted manually. Right panel: quantification of the relative number of 
autophagosomes in the cell. Treatment with CCCP resulted in reduced 
autophagosome formation in SQSTM1-deficient cells. n=3, 150 cells per experiment. 
(D) SQSTM1/p62 variant and control cell lines were treated for 24 and 48 h with the 
protonophore CCCP (20 µM). Treatment with CCCP resulted in reduced LC3II levels 
formation in SQSTM1/p62-deficient cells. Right panel: quantification of the relative 
LC3II protein levels using ImageJ software. 
(B-D) *, p ≤ 0.05; **, p ≤ 0.01; two-tailed unpaired t-test. Error bars indicate ± SEM 
from the mean of three replicates. 
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Table 1. Genetic and Clinical Findings in Individuals with Biallelic SQSTM1 Loss-of-function Variants 
ID sex 
SQSTM1 variants  Phenotypic features  MRI findings 
cDNA (NM_003900.4) 
protein (NP_003891.1) 
 AaO  
[y] 
AaLE 
[y] 
Gait 
abn. 
Ataxia Dystonia Dysarthria Gaze 
palsy 
MND Cognitive  
decline 
 CA Iron 
F1:II.1 m c.[2T>A];[2T>A] 
p.[?];[?] 
 
10 45 +* +* + + + +L  -  nd nd 
F1:II.3 f c.[2T>A];[2T>A] 
p.[?];[?] 
 
12 42 +* + + + + +U/L +*  - + 
F1:II.6 f c.[2T>A];[2T>A] 
p.[?];[?] 
 
15 33 +* +* + + - - +  - + 
F2:II.2 f  c.[311_312del];[311_312del] 
p.[Glu104Valfs48*];[Glu104Valfs48*] 
 
10 31 +* +* + + + - +*  + - 
F2:II.3 f c.[311_312del];[311_312del] 
p.[Glu104Valfs48*];[Glu104Valfs48*] 
 
10 18 +* +* + (+) + - +*  + - 
F2:II.z f c.[311_312del];[311_312del] 
p.[Glu104Valfs48*];[Glu104Valfs48*] 
 
10 12 +* +* + (+) + - +*  + - 
F3:II.1 f c.[286C>T];[286C>T] 
p.[Arg96*];[Arg96*] 
 
7 18 + + - + - - +  + - 
F4:II.1 f c.[286C>T];[286C>T] 
p.[Arg96*];[Arg96*] 
 
8 33 + +* - + + - +  - - 
F4:II.4 m c.[286C>T];[286C>T] 
p.[Arg96*];[Arg96*] 
 
8 17 + +* + + + - +  - - 
AaLE, age at last examination; AaO, age at onset; abn., abnormalities; CA, cerebellar atrophy; f, female; m, male; MND, motor neuron disorder (L, lower MND; U/L, upper and lower 
MND); nd, not done; nk, not known; y, years; *, among the presenting symptoms 
